APA (7th ed.) Citation

Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D'Rozario, J., Owen, C. J., Assouline, S., . . . Kater, A. P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140(8), 839-850. https://doi.org/10.1182/blood.2021015014

Chicago Style (17th ed.) Citation

Seymour, John F., et al. "Enduring Undetectable MRD and Updated Outcomes in Relapsed/refractory CLL After Fixed-duration Venetoclax-rituximab." Blood 140, no. 8 (2022): 839-850. https://doi.org/10.1182/blood.2021015014.

MLA (9th ed.) Citation

Seymour, John F., et al. "Enduring Undetectable MRD and Updated Outcomes in Relapsed/refractory CLL After Fixed-duration Venetoclax-rituximab." Blood, vol. 140, no. 8, 2022, pp. 839-850, https://doi.org/10.1182/blood.2021015014.